Paul M Young

List of Publications by Citations

249 papers	5,789 citations	41 h-index	59 g-index
259 ext. papers	6,579 ext. citations	5 avg, IF	5.92 L-index

#	Paper	IF	Citations
249	Recent advances in curcumin nanoformulation for cancer therapy. *Expert Opinion on Drug Delivery*, **2014**, 11, 1183-201	8	157
248	The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations. *International Journal of Pharmaceutics*, **2002**, 246, 47-59	6.5	130
247	Combination of Silver Nanoparticles and Curcumin Nanoparticles for Enhanced Anti-biofilm Activities. *Journal of Agricultural and Food Chemistry*, **2016**, 64, 2513-22	5.7	107
246	Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges. *Asian Journal of Pharmaceutical Sciences*, **2015**, 10, 481-489	9	98
245	The influence of dose on the performance of dry powder inhalation systems. *International Journal of Pharmaceutics*, **2005**, 296, 26-33	6.5	90
244	Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages. *Expert Opinion on Drug Delivery*, **2015**, 12, 1009-26	8	88
243	Visualization of the crystallization of lactose from the amorphous state. *Journal of Pharmaceutical Sciences*, **2004**, 93, 155-64	3.9	88
242	Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes. *Pharmaceutics*, **2019**, 11,	6.4	87
241	Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model. *Drug Development and Industrial Pharmacy*, **2010**, 36, 1207-14	3.6	86
240	Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems. *Pharmaceutical Research*, **2007**, 24, 963-70	4.5	85
239	The influence of lactose pseudopolymorphic form on salbutamol sulfate-lactose interactions in DPI formulations. *Drug Development and Industrial Pharmacy*, **2008**, 34, 992-1001	3.6	83
238	Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease. *European Journal of Pharmaceutical Sciences*, **2010**, 40, 239-47	5.1	78
237	Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. *European Journal of Pharmaceutics and Biopharmaceutics*, **2008**, 70, 145-52	5.7	77
236	Micro-particle corrugation, adhesion and inhalation aerosol efficiency. *European Journal of Pharmaceutical Sciences*, **2008**, 35, 12-8	5.1	74
235	Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation. *Pharmaceutical Research*, **2006**, 23, 2556-65	4.5	71
234	A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics. *European Journal of Pharmaceutics and Biopharmaceutics*, **2013**, 83, 285-92	5.7	70
233	Delivery of antibiotics to the respiratory tract: an update. *Expert Opinion on Drug Delivery*, **2009**, 6, 897-905	8	70

232	Investigation into the effect of humidity on drug-drug interactions using the atomic force microscope. *Journal of Pharmaceutical Sciences*, **2003**, 92, 815-22	3.9	65
231	Superhydrophobic, nanotextured polyvinyl chloride films for delaying Pseudomonas aeruginosa attachment to intubation tubes and medical plastics. *Acta Biomaterialia*, **2012**, 8, 1881-90	10.8	64
230	The influence of drug morphology on aerosolisation efficiency of dry powder inhaler formulations. *Journal of Pharmaceutical Sciences*, **2008**, 97, 2780-8	3.9	64
229	Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia. *Pharmaceutical Research*, **2012**, 29, 3335-46	4.5	63
228	The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate. *European Journal of Pharmaceutical Sciences*, **2004**, 22, 235-40	5.1	61
227	Cospray dried antibiotics for dry powder lung delivery. *Journal of Pharmaceutical Sciences*, **2008**, 97, 3356-66	3.9	60
226	Solid lipid microparticles as an approach to drug delivery. *Expert Opinion on Drug Delivery*, **2015**, 12, 583-99	8	57
225	The use of computational approaches in inhaler development. *Advanced Drug Delivery Reviews*, **2012**, 64, 312-22	18.5	54
224	Solid lipid budesonide microparticles for controlled release inhalation therapy. *AAPS Journal*, **2009**, 11, 771-8	3.7	54
223	The influence of mechanical processing of dry powder inhaler carriers on drug aerosolization performance. *Journal of Pharmaceutical Sciences*, **2007**, 96, 1331-41	3.9	53
222	Pharmaceutical applications of the Calu-3 lung epithelia cell line. *Expert Opinion on Drug Delivery*, **2013**, 10, 1287-302	8	49
221	The surface roughness of lactose particles can be modulated by wet-smoothing using a high-shear mixer. *AAPS PharmSciTech*, **2004**, 5, e60	3.9	49
220	Saturated fatty acids, obesity, and the nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in asthmatic patients. *Journal of Allergy and Clinical Immunology*, **2019**, 143, 305-315	11.5	47
219	Lactose composite carriers for respiratory delivery. *Pharmaceutical Research*, **2009**, 26, 802-10	4.5	47
218	Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency. *Pharmaceutical Research*, **2009**, 26, 1084-92	4.5	47
217	The influence of relative humidity on the cohesion properties of micronized drugs used in inhalation therapy. *Journal of Pharmaceutical Sciences*, **2004**, 93, 753-61	3.9	47
216	Surface energy and interparticle forces correlations in model pMDI formulations. *Pharmaceutical Research*, **2005**, 22, 816-25	4.5	47
215	Across the pulmonary epithelial barrier: Integration of physicochemical properties and human cell models to study pulmonary drug formulations. *Pharmacology & Therapeutics*, **2014**, 144, 235-52	13.9	44

214	Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia. *Molecular Pharmaceutics*, **2012**, 9, 1717-26	5.6	44
213	Quercetin solid lipid microparticles: a flavonoid for inhalation lung delivery. *European Journal of Pharmaceutical Sciences*, **2013**, 49, 278-85	5.1	44
212	Magnetised thermo responsive lipid vehicles for targeted and controlled lung drug delivery. *Pharmaceutical Research*, **2012**, 29, 2456-67	4.5	41
211	Particle size dependence of polymorphism in spray-dried mannitol. *European Journal of Pharmaceutical Sciences*, **2011**, 44, 41-8	5.1	41
210	Measuring charge and mass distributions in dry powder inhalers using the electrical Next Generation Impactor (eNGI). *European Journal of Pharmaceutical Sciences*, **2009**, 38, 88-94	5.1	41
209	Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems. *Pharmaceutical Research*, **2010**, 27, 1367-76	4.5	41
208	A Review of Respiratory Anatomical Development, Air Flow Characterization and Particle Deposition. *International Journal of Environmental Research and Public Health*, **2020**, 17,	4.6	40
207	Epithelial profiling of antibiotic controlled release respiratory formulations. *Pharmaceutical Research*, **2011**, 28, 2327-38	4.5	40
206	In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. *European Journal of Pharmaceutics and Biopharmaceutics*, **2014**, 86, 83-9	5.7	39
205	The use of inverse gas chromatography for the study of lactose and pharmaceutical materials used in dry powder inhalers. *Advanced Drug Delivery Reviews*, **2012**, 64, 285-93	18.5	39
204	The influence of drug loading on formulation structure and aerosol performance in carrier based dry powder inhalers. *International Journal of Pharmaceutics*, **2011**, 416, 129-35	6.5	39
203	The use of organic vapor sorption to determine low levels of amorphous content in processed pharmaceutical powders. *Drug Development and Industrial Pharmacy*, **2007**, 33, 91-7	3.6	39
202	The effect of mechanical processing on surface stability of pharmaceutical powders: visualization by atomic force microscopy. *Journal of Pharmaceutical Sciences*, **2003**, 92, 611-20	3.9	39
201	Under pressure: predicting pressurized metered dose inhaler interactions using the atomic force microscope. *Journal of Colloid and Interface Science*, **2003**, 262, 298-302	9.3	39
200	Effect of humidity on aerosolization of micronized drugs. *Drug Development and Industrial Pharmacy*, **2003**, 29, 959-66	3.6	39
199	The potential to treat lung cancer via inhalation of repurposed drugs. *Advanced Drug Delivery Reviews*, **2018**, 133, 107-130	18.5	39
198	Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders. *Expert Opinion on Drug Delivery*, **2019**, 16, 453-466	8	37
197	Overcoming dose limitations using the orbital( ) multi-breath dry powder inhaler. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2014**, 27, 138-47	3.8	37

196	Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 2535-40	5.9	37
195	On the physical transformations of processed pharmaceutical solids. *Micron*, **2005**, 36, 519-24	2.3	37
194	Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. *European Journal of Pharmaceutics and Biopharmaceutics*, **2016**, 107, 223-33	5.7	36
193	A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. *Pharmaceutical Research*, **2014**, 31, 1239-53	4.5	36
192	Composite carriers improve the aerosolisation efficiency of drugs for respiratory delivery. *Journal of Aerosol Science*, **2008**, 39, 82-93	4.3	36
191	Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. *Expert Opinion on Drug Delivery*, **2011**, 8, 1205-20	8	35
190	Does carrier size matter? A fundamental study of drug aerosolisation from carrier based dry powder inhalation systems. *International Journal of Pharmaceutics*, **2011**, 413, 1-9	6.5	35
189	The influence of flow rate on the aerosol deposition profile and electrostatic charge of single and combination metered dose inhalers. *Pharmaceutical Research*, **2009**, 26, 2639-46	4.5	34
188	Non-cytotoxic silver nanoparticle-polyvinyl alcohol hydrogels with anti-biofilm activity: designed as coatings for endotracheal tube materials. *Biofouling*, **2014**, 30, 773-88	3.3	33
187	Role of agglomeration in the dispersion of salmeterol xinafoate from mixtures for inhalation with differing drug to fine lactose ratios. *Journal of Pharmaceutical Sciences*, **2008**, 97, 3140-52	3.9	33
186	Surface energy of microcrystalline cellulose determined by capillary intrusion and inverse gas chromatography. *AAPS Journal*, **2008**, 10, 494-503	3.7	33
185	Novel temperature controlled surface dissolution of excipient particles for carrier based dry powder inhaler formulations. *Drug Development and Industrial Pharmacy*, **2006**, 32, 243-51	3.6	33
184	A novel inhalable form of rifapentine. *Journal of Pharmaceutical Sciences*, **2014**, 103, 1411-21	3.9	32
183	Silver nanoparticles enhance Pseudomonas aeruginosa PAO1 biofilm detachment. *Drug Development and Industrial Pharmacy*, **2014**, 40, 719-29	3.6	32
182	Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 1: influence of polymer concentration on physical and in vitro characteristics. *European Journal of Pharmaceutics and Biopharmaceutics*, **2008**, 69, 486-95	5.7	32
181	Comparative study of erythritol and lactose monohydrate as carriers for inhalation: atomic force microscopy and in vitro correlation. *European Journal of Pharmaceutical Sciences*, **2006**, 27, 243-51	5.1	32
180	Development of an inhaled controlled release voriconazole dry powder formulation for the treatment of respiratory fungal infection. *Molecular Pharmaceutics*, **2015**, 12, 2001-9	5.6	31
179	Preparation and evaluation of controlled release microparticles for respiratory protein therapy. *Journal of Pharmaceutical Sciences*, **2009**, 98, 2709-17	3.9	31

178	Continued investigation into the influence of loaded dose on the performance of dry powder inhalers: surface smoothing effects. *Drug Development and Industrial Pharmacy*, **2006**, 32, 1135-8	3.6	31
177	Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages. *European Journal of Pharmaceutical Sciences*, **2016**, 86, 20-8	5.1	28
176	The use of colloid probe microscopy to predict aerosolization performance in dry powder inhalers: AFM and in vitro correlation. *Journal of Pharmaceutical Sciences*, **2006**, 95, 1800-9	3.9	28
175	In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers. *Pharmaceutical Research*, **2007**, 24, 125-35	4.5	28
174	Synthesis and Characterization of Inhalable Flavonoid Nanoparticle for Lung Cancer Cell Targeting. *Journal of Biomedical Nanotechnology*, **2016**, 12, 371-86	4	27
173	Influence of storage relative humidity on the dispersion of salmeterol xinafoate powders for inhalation. *Journal of Pharmaceutical Sciences*, **2009**, 98, 1015-27	3.9	27
172	Introduction of the electrical next generation impactor (eNGI) and investigation of its capabilities for the study of pressurized metered dose inhalers. *Pharmaceutical Research*, **2009**, 26, 431-7	4.5	26
171	In vitro cell integrated impactor deposition methodology for the study of aerodynamically relevant size fractions from commercial pressurised metered dose inhalers. *Pharmaceutical Research*, **2014**, 31, 1779-87	4.5	25
170	Primary Air-Liquid Interface Culture of Nasal Epithelium for Nasal Drug Delivery. *Molecular Pharmaceutics*, **2016**, 13, 2242-52	5.6	24
169	The effect of ethanol on the formation and physico-chemical properties of particles generated from budesonide solution-based pressurized metered-dose inhalers. *Drug Development and Industrial Pharmacy*, **2013**, 39, 1625-37	3.6	24
168	Inhaled gene delivery: a formulation and delivery approach. *Expert Opinion on Drug Delivery*, **2017**, 14, 319-330	8	24
167	The Use of AFM and Surface Energy Measurements to Investigate Drug-Canister Material Interactions in a Model Pressurized Metered Dose Inhaler Formulation. *Aerosol Science and Technology*, **2006**, 40, 227-236	3.4	24
166	Investigation into the influence of polymeric stabilizing excipients on inter-particulate forces in pressurised metered dose inhalers. *International Journal of Pharmaceutics*, **2006**, 320, 58-63	6.5	24
165	Particle synergy and aerosol performance in non-aqueous liquid of two combinations metered dose inhalation formulations: an AFM and Raman investigation. *Journal of Colloid and Interface Science*, **2011**, 361, 649-55	9.3	23
164	In vitro biological activity of resveratrol using a novel inhalable resveratrol spray-dried formulation. *International Journal of Pharmaceutics*, **2015**, 491, 190-7	6.5	22
163	From single excipients to dual excipient platforms in dry powder inhaler products. *International Journal of Pharmaceutics*, **2016**, 514, 374-383	6.5	22
162	Highly respirable dry powder inhalable formulation of voriconazole with enhanced pulmonary bioavailability. *Expert Opinion on Drug Delivery*, **2016**, 13, 183-93	8	22
161	Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation. *Drug Development and Industrial Pharmacy*, **2016**, 42, 1660-8	3.6	22

160	Surface energy changes and their relationship with the dispersibility of salmeterol xinafoate powders for inhalation after storage at high RH. *European Journal of Pharmaceutical Sciences*, **2009**, 38, 347-54	5.1	22
159	Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines. *Journal of Pharmaceutical and Biomedical Analysis*, **2010**, 51, 853-7	3.5	22
158	Scanning white-light interferometry as a novel technique to quantify the surface roughness of micron-sized particles for inhalation. *Langmuir*, **2008**, 24, 11307-12	4	22
157	The utility of 3D-printed airway stents to improve treatment strategies for central airway obstructions. *Drug Development and Industrial Pharmacy*, **2019**, 45, 1-10	3.6	22
156	Cell-based therapies for the treatment of idiopathic pulmonary fibrosis (IPF) disease. *Expert Opinion on Biological Therapy*, **2016**, 16, 375-87	5.4	21
155	Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases. *AAPS Journal*, **2014**, 16, 269-80	3.7	21
154	Towards the bioequivalence of pressurised metered dose inhalers 1: design and characterisation of aerodynamically equivalent beclomethasone dipropionate inhalers with and without glycerol as a non-volatile excipient. *European Journal of Pharmaceutics and Biopharmaceutics*, **2014**, 86, 31-7	5.7	21
153	The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia. *Molecular Pharmaceutics*, **2013**, 10, 2915-24	5.6	21
152	Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of the influence of grid structures for agglomerated systems. *Journal of Pharmaceutical Sciences*, **2011**, 100, 4710-21	3.9	21
151	Does electrostatic charge affect powder aerosolisation?. *Journal of Pharmaceutical Sciences*, **2010**, 99, 2455-61	3.9	21
150	Dynamic vapor sorption properties of sodium starch glycolate disintegrants. *Pharmaceutical Development and Technology*, **2005**, 10, 249-59	3.4	21
149	The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer. *Expert Opinion on Drug Delivery*, **2017**, 14, 937-957	8	20
148	Multiple dosing of simvastatin inhibits airway mucus production of epithelial cells: implications in the treatment of chronic obstructive airway pathologies. *European Journal of Pharmaceutics and Biopharmaceutics*, **2013**, 84, 566-72	5.7	20
147	Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity. *European Journal of Pharmaceutical Sciences*, **2009**, 37, 442-50	5.1	20
146	Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. *Drug Development and Industrial Pharmacy*, **2015**, 41, 859-65	3.6	19
145	Preparation and in vitro evaluation of salbutamol-loaded lipid microparticles for sustained release pulmonary therapy. *Journal of Microencapsulation*, **2012**, 29, 225-33	3.4	19
144	Fluticasone uptake across Calu-3 cells is mediated by salmeterol when deposited as a combination powder inhaler. *Respirology*, **2013**, 18, 1197-201	3.6	19
143	Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of impaction effects for agglomerated systems. *Journal of Pharmaceutical Sciences*, **2011**, 100, 2744-54	3.9	19

142	Recent advances in controlled release pulmonary therapy. *Current Drug Delivery*, **2009**, 6, 404-14	3.2	19
141	The development of a novel high-dose pressurized aerosol dry-powder device (PADD) for the delivery of pumactant for inhalation therapy. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2004**, 17, 123-8		19
140	Salbutamol sulfate absorption across Calu-3 bronchial epithelia cell monolayer is inhibited in the presence of common anionic NSAIDs. *Journal of Asthma*, **2013**, 50, 334-41	1.9	18
139	Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro. *European Journal of Pharmaceutics and Biopharmaceutics*, **2014**, 86, 38-45	5.7	18
138	Application of a Thermosensitive In Situ Gel of Chitosan-Based Nasal Spray Loaded with Tranexamic Acid for Localised Treatment of Nasal Wounds. *AAPS PharmSciTech*, **2019**, 20, 299	3.9	17
137	Dry powder formulation of simvastatin. *Expert Opinion on Drug Delivery*, **2015**, 12, 857-68	8	17
136	Polymer coating of carrier excipients modify aerosol performance of adhered drugs used in dry powder inhalation therapy. *International Journal of Pharmaceutics*, **2012**, 438, 150-9	6.5	17
135	Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery. *Drug Development and Industrial Pharmacy*, **2017**, 43, 1510-1518	3.6	16
134	A review of co-milling techniques for the production of high dose dry powder inhaler formulation. *Drug Development and Industrial Pharmacy*, **2017**, 43, 1229-1238	3.6	16
133	Repurposing of statins via inhalation to treat lung inflammatory conditions. *Advanced Drug Delivery Reviews*, **2018**, 133, 93-106	18.5	16
132	Novel simvastatin inhalation formulation and characterisation. *AAPS PharmSciTech*, **2014**, 15, 956-62	3.9	16
131	The potential use of Raman mapping to investigate in vitro deposition of combination pressurized metered-dose inhalers. *AAPS Journal*, **2004**, 6, e32	3.7	16
130	Chemical characterisation of sodium starch glycolate particles. *International Journal of Pharmaceutics*, **2002**, 240, 67-78	6.5	16
129	The development of a single-use, capsule-free multi-breath tobramycin dry powder inhaler for the treatment of cystic fibrosis. *International Journal of Pharmaceutics*, **2016**, 514, 392-398	6.5	16
128	Biological Effects of Simvastatin Formulated as pMDI on Pulmonary Epithelial Cells. *Pharmaceutical Research*, **2016**, 33, 92-101	4.5	15
127	Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?. *European Journal of Pharmaceutics and Biopharmaceutics*, **2015**, 93, 320-7	5.7	15
126	The use of fatty acids as absorption enhancer for pulmonary drug delivery. *International Journal of Pharmaceutics*, **2018**, 541, 93-100	6.5	15
125	Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers. *Journal of Pharmacy and Pharmacology*, **2012**, 64, 1245-53	4.8	15

124	Incorporation of quercetin in respirable lipid microparticles: effect on stability and cellular uptake on A549 pulmonary alveolar epithelial cells. *Colloids and Surfaces B: Biointerfaces*, **2013**, 112, 322-9	6	15
123	The contribution of different formulation components on the aerosol charge in carrier-based dry powder inhaler systems. *Pharmaceutical Research*, **2010**, 27, 1325-36	4.5	15
122	Artesunate-clindamycin multi-kinetics and site-specific oral delivery system for antimalaric combination products. *Journal of Controlled Release*, **2010**, 146, 54-60	11.7	15
121	Euler□agrange approach to investigate respiratory anatomical shape effects on aerosol particle transport and deposition. *Toxicology Research and Application*, **2019**, 3, 239784731989467	0.8	15
120	Co-milled API-lactose systems for inhalation therapy: impact of magnesium stearate on physico-chemical stability and aerosolization performance. *Drug Development and Industrial Pharmacy*, **2017**, 43, 980-988	3.6	14
119	Allergic environment enhances airway epithelial pro-inflammatory responses to rhinovirus infection. *Clinical Science*, **2017**, 131, 499-509	6.5	14
118	Knowledge that people with intellectual disabilities have of their inhaled asthma medications: messages for pharmacists. *International Journal of Clinical Pharmacy*, **2016**, 38, 135-43	2.3	14
117	The solid-state and morphological characteristics of particles generated from solution-based metered dose inhalers: Influence of ethanol concentration and intrinsic drug properties. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, **2014**, 443, 345-355	5.1	14
116	Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease?. *Expert Opinion on Pharmacotherapy*, **2011**, 12, 1913-32	4	14
115	Modelling of molecular phase transitions in pharmaceutical inhalation compounds: an in silico approach. *European Journal of Pharmaceutics and Biopharmaceutics*, **2011**, 78, 83-9	5.7	14
114	A novel apparatus for the determination of solubility in pressurized metered dose inhalers. *Drug Development and Industrial Pharmacy*, **2006**, 32, 1159-63	3.6	14
113	Dosing challenges in respiratory therapies. *International Journal of Pharmaceutics*, **2018**, 548, 659-671	6.5	14
112	Combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate for the treatment of inflammatory lung diseases: An in vitro study. *European Journal of Pharmaceutical Sciences*, **2018**, 120, 96-106	5.1	13
111	The formulation of a pressurized metered dose inhaler containing theophylline for inhalation. *European Journal of Pharmaceutical Sciences*, **2015**, 76, 68-72	5.1	13
110	Understanding lactose behaviour during storage by monitoring surface energy change using inverse gas chromatography. *Dairy Science and Technology*, **2010**, 90, 271-285		13
109	Delivery of theophylline as dry powder for inhalation. *Asian Journal of Pharmaceutical Sciences*, **2015**, 10, 520-527	9	12
108	Isothermal calorimetry: a predictive tool to model drug-propellant interactions in pressurized metered dose systems. *International Journal of Pharmaceutics*, **2014**, 461, 301-9	6.5	12
107	A Ssoft spotSfor drug transport: modulation of cell stiffness using fatty acids and its impact on drug transport in lung model. *Journal of Materials Chemistry B*, **2015**, 3, 2583-2589	7.3	12

106	A Review of Electrostatic Measurement Techniques for Aerosol Drug Delivery to the Lung: Implications in Aerosol Particle Deposition. *Journal of Adhesion Science and Technology*, **2011**, 25, 385-405	2	12
105	High-Speed Laser Image Analysis of Plume Angles for Pressurised Metered Dose Inhalers: The Effect of Nozzle Geometry. *AAPS PharmSciTech*, **2017**, 18, 782-789	3.9	11
104	Tuning aerosol performance using the multibreath Orbital dry powder inhaler device: controlling delivery parameters and aerosol performance via modification of puck orifice geometry. *Journal of Pharmaceutical Sciences*, **2015**, 104, 2169-76	3.9	11
103	Aerosol particle generation from solution-based pressurized metered dose inhalers: a technical overview of parameters that influence respiratory deposition. *Pharmaceutical Development and Technology*, **2015**, 20, 897-910	3.4	11
102	Limitations of high dose carrier based formulations. *International Journal of Pharmaceutics*, **2018**, 544, 141-152	6.5	11
101	Microfluidic production of endoskeleton droplets with controlled size and shape. *Powder Technology*, **2018**, 329, 129-136	5.2	11
100	Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and in vitro deposition study. *Journal of Microencapsulation*, **2016**, 33, 735-742	3.4	11
99	Antibiotic transport across bronchial epithelial cells: Effects of molecular weight, LogP and apparent permeability. *European Journal of Pharmaceutical Sciences*, **2016**, 83, 45-51	5.1	11
98	Comparison of spray congealing and melt emulsification methods for the incorporation of the water-soluble salbutamol sulphate in lipid microparticles. *Pharmaceutical Development and Technology*, **2013**, 18, 266-73	3.4	11
97	The role of direct support professionals in asthma management. *Journal of Intellectual and Developmental Disability*, **2015**, 40, 342-353	1.9	11
96	Inhalable tranexamic acid for haemoptysis treatment. *European Journal of Pharmaceutics and Biopharmaceutics*, **2015**, 93, 311-9	5.7	11
95	Mannitol delivery by vibrating mesh nebulisation for enhancing mucociliary clearance. *Journal of Pharmaceutical Sciences*, **2011**, 100, 2693-702	3.9	11
94	Delivery of high solubility polyols by vibrating mesh nebulizer to enhance mucociliary clearance. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2012**, 25, 297-305	3.8	11
93	Motivations and Key Features for a Wearable Device for Continuous Monitoring of Breathing: A Web-Based Survey. *JMIR Biomedical Engineering*, **2017**, 2, e1	1.3	11
92	Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis. *European Journal of Pharmaceutical Sciences*, **2020**, 142, 105098	5.1	11
91	An investigation of surface properties, local elastic modulus and interaction with simulated pulmonary surfactant of surface modified inhalable voriconazole dry powders using atomic force microscopy. *RSC Advances*, **2016**, 6, 25789-25798	3.7	11
90	Curcumin Nanoparticles Attenuate Production of Pro-inflammatory Markers in Lipopolysaccharide-Induced Macrophages. *Pharmaceutical Research*, **2016**, 33, 315-27	4.5	10
89	Revealing pMDI Spray Initial Conditions: Flashing, Atomisation and the Effect of Ethanol. *Pharmaceutical Research*, **2017**, 34, 718-729	4.5	10

88	Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection. *Pharmaceutical Research*, **2018**, 35, 50	4.5	10
87	Could simvastatin be considered as a potential therapy for chronic lung diseases? A debate on the pros and cons. *Expert Opinion on Drug Delivery*, **2016**, 13, 1407-20	8	10
86	The use of atomic force microscopy to study the conditioning of micronised budesonide. *International Journal of Pharmaceutics*, **2008**, 357, 314-7	6.5	10
85	Respiratory medication use in an Australian developmental disability clinic population: messages for health care professionals. *Australian Journal of Primary Health*, **2014**, 20, 278-84	1.4	10
84	Mono- and Cocultures of Bronchial and Alveolar Epithelial Cells Respond Differently to Proinflammatory Stimuli and Their Modulation by Salbutamol and Budesonide. *Molecular Pharmaceutics*, **2015**, 12, 2625-32	5.6	9
83	Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler. *Pharmaceutical Research*, **2015**, 32, 2144-53	4.5	9
82	Temporally and Spatially Resolved x-ray Fluorescence Measurements of in-situ Drug Concentration in Metered-Dose Inhaler Sprays. *Pharmaceutical Research*, **2016**, 33, 816-25	4.5	9
81	A novel high-speed imaging technique to predict the macroscopic spray characteristics of solution based pressurised metered dose inhalers. *Pharmaceutical Research*, **2014**, 31, 2963-74	4.5	9
80	Implications and emerging control strategies for ventilator-associated infections. *Expert Review of Anti-Infective Therapy*, **2015**, 13, 379-93	5.5	9
79	The influence of micronised particulates on the aerosolisation properties of pressurised metered dose inhalers. *Journal of Aerosol Science*, **2009**, 40, 324-337	4.3	9
78	Effect of polyunsaturated fatty acids (PUFAs) on airway epithelial cellsStight junction. *Pulmonary Pharmacology and Therapeutics*, **2016**, 40, 30-8	3.5	8
77	Inhaled simvastatin nanoparticles for inflammatory lung disease. *Nanomedicine*, **2017**, 12, 2471-2485	5.6	8
76	Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. *International Journal of Antimicrobial Agents*, **2015**, 45, 319-23	14.3	8
75	The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. *Journal of Pharmacy and Pharmacology*, **2014**, 66, 639-45	4.8	8
74	Recent advances in understanding the influence of composite-formulation properties on the performance of dry powder inhalers. *Physica B: Condensed Matter*, **2007**, 394, 315-319	2.8	8
73	Development and Evaluation of Paclitaxel and Curcumin Dry Powder for Inhalation Lung Cancer Treatment. *Pharmaceutics*, **2020**, 13,	6.4	8
72	Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. *Pharmaceutical Development and Technology*, **2014**, 19, 911-21	3.4	7
71	Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline. *Drug Delivery and Translational Research*, **2014**, 4, 256-67	6.2	7

70	The influence of actuator materials and nozzle designs on electrostatic charge of pressurised metered dose inhaler (pMDI) formulations. *Pharmaceutical Research*, **2014**, 31, 1325-37	4.5	7
69	Microstructural analysis of porous composite materials: dynamic imaging of drug dissolution and diffusion through porous matrices. *AAPS Journal*, **2008**, 10, 560-4	3.7	7
68	In-vitro and particle image velocimetry studies of dry powder inhalers. *International Journal of Pharmaceutics*, **2021**, 592, 119966	6.5	7
67	Delivery of pDNA to lung epithelial cells using PLGA nanoparticles formulated with a cell-penetrating peptide: understanding the intracellular fate. *Drug Development and Industrial Pharmacy*, **2020**, 46, 427-442	3.6	6
66	A locally constrained statistical shape model for robust nasal cavity segmentation in computed tomography **2016**,		6
65	Insights into Spray Development from Metered-Dose Inhalers Through Quantitative X-ray Radiography. *Pharmaceutical Research*, **2016**, 33, 1249-58	4.5	6
64	The ability of people with intellectual disability to use inhalers--an exploratory mixed methods study. *Journal of Asthma*, **2016**, 53, 86-93	1.9	6
63	Co-Spray-Dried Urea Cross-Linked Hyaluronic Acid and Sodium Ascorbyl Phosphate as Novel Inhalable Dry Powder Formulation. *Journal of Pharmaceutical Sciences*, **2019**, 108, 2964-2971	3.9	6
62	Development of an in vivo ovine dry powder inhalation model for the evaluation of conventional and controlled release microparticles. *AAPS Journal*, **2009**, 11, 465-8	3.7	6
61	Dynamic electrostatic charge of lactose-salbutamol sulphate powder blends dispersed from a Cyclohaler . *Drug Development and Industrial Pharmacy*, **2011**, 37, 1365-75	3.6	6
60	Drug Release from Inert Spherical Matrix Systems Using Monte Carlo Simulations. *Current Drug Delivery*, **2017**, 14, 65-72	3.2	6
59	Simvastatin Nanoparticles Reduce Inflammation in LPS-Stimulated Alveolar Macrophages. *Journal of Pharmaceutical Sciences*, **2019**, 108, 3890-3897	3.9	5
58	Assessing Aerosol Performance of a Dry Powder Carrier Formulation with Increasing Doses Using a Novel Inhaler. *AAPS PharmSciTech*, **2019**, 20, 94	3.9	5
57	Determination of physical and chemical stability in pressurised metered dose inhalers: potential new techniques. *Expert Opinion on Drug Delivery*, **2015**, 12, 1661-75	8	5
56	An automated segmentation framework for nasal computational fluid dynamics analysis in computed tomography. *Computers in Biology and Medicine*, **2019**, 115, 103505	7	5
55	Twenty years of HFA pMDI patents: facts and perspectives. *Journal of Pharmacy and Pharmacology*, **2012**, 64, 1209-16	4.8	5
54	Parameters affecting drug release from inert matrices. 1: Monte Carlo simulation. *Pharmaceutical Development and Technology*, **2012**, 17, 344-52	3.4	5
53	An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line. *European Journal of Pharmaceutics and Biopharmaceutics*, **2020**, 156, 121-130	5.7	5

52	Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part II: the effect of nanoparticle charge. *Nanomedicine*, **2020**, 15, 1947-1963	5.6	5
51	In vitro characterization of physico-chemical properties, cytotoxicity, bioactivity of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate nasal powder formulation. *International Journal of Pharmaceutics*, **2019**, 558, 341-350	6.5	5
50	Real-time quantitative monitoring of nasal drug delivery by a nasal epithelial mucosa-on-a-chip model. *Expert Opinion on Drug Delivery*, **2021**, 18, 803-818	8	5
49	Investigation into the Manufacture and Properties of Inhalable High-Dose Dry Powders Produced by Comilling API and Lactose with Magnesium Stearate. *AAPS PharmSciTech*, **2017**, 18, 2248-2259	3.9	4
48	The effect of non-specific tight junction modulators on the transepithelial transport of poorly permeable drugs across airway epithelial cells. *Journal of Drug Targeting*, **2017**, 25, 342-349	5.4	4
47	The Effect of Active Pharmaceutical Ingredients on Aerosol Electrostatic Charges from Pressurized Metered Dose Inhalers. *Pharmaceutical Research*, **2015**, 32, 2928-36	4.5	4
46	Modification of disodium cromoglycate passage across lung epithelium in vitro via incorporation into polymeric microparticles. *AAPS Journal*, **2012**, 14, 79-86	3.7	4
45	Aerosol tribocharging and its relation to the deposition of Oxis Turbuhaler in the electrical next generation impactor. *Journal of Pharmaceutical Sciences*, **2011**, 100, 5270-80	3.9	4
44	Novel nano-cellulose excipient for generating non-Newtonian droplets for targeted nasal drug delivery. *Drug Development and Industrial Pharmacy*, **2017**, 43, 1729-1733	3.6	4
43	Drug distribution transients in solution and suspension-based pressurised metered dose inhaler sprays. *International Journal of Pharmaceutics*, **2019**, 566, 463-475	6.5	3
42	Evolved gas analysis during thermal degradation of salbutamol sulphate. *Journal of Thermal Analysis and Calorimetry*, **2015**, 120, 789-794	4.1	3
41	The effect of actuator nozzle designs on the electrostatic charge generated in pressurised metered dose inhaler aerosols. *Pharmaceutical Research*, **2015**, 32, 1237-48	4.5	3
40	Effect of continuous positive airway pressure treatment on permeability, inflammation and mucus production of human epithelial cells. *ERJ Open Research*, **2020**, 6,	3.5	3
39	The Formation of Aerosol Particles from Solution-Based Pressurized Metered Dose Inhalers and Implications of Incomplete Droplet Drying: Theoretical and Experimental Comparison. *Aerosol Science and Technology*, **2015**, 49, 1090-1099	3.4	3
38	Preparation and evaluation of single and co-engineered combination inhalation carrier formulations for the treatment of asthma. *Journal of Pharmaceutical Sciences*, **2012**, 101, 4267-76	3.9	3
37	Formulation of Inhalation Medicines **2013**, 31-45		3
36	Interaction of moisture with sodium starch glycolate. *Pharmaceutical Development and Technology*, **2007**, 12, 211-6	3.4	3
35	Dynamic Vapor Sorption Properties of Sodium Starch Glycolate Disintegrants. *Pharmaceutical Development and Technology*, **2005**, 10, 249-259	3.4	3

34	Paclitaxel-eluting silicone airway stent for preventing granulation tissue growth and lung cancer relapse in central airway pathologies. *Expert Opinion on Drug Delivery*, **2020**, 17, 1631-1645	8	3
33	Exploring the impact of sample flowrate on in vitro measurements of metered dose inhaler performance. *International Journal of Pharmaceutics*, **2016**, 514, 420-427	6.5	3
32	Effect of Dosing Cup Size on the Aerosol Performance of High-Dose Carrier-Based Formulations in a Novel Dry Powder Inhaler. *Journal of Pharmaceutical Sciences*, **2019**, 108, 949-959	3.9	3
31	Human Stimulus Factor Is a Promising Peptide for Delivery of Therapeutics. *Journal of Pharmaceutical Sciences*, **2019**, 108, 1401-1403	3.9	2
30	Image-based ciliary beating frequency estimation for therapeutic assessment on defective mucociliary clearance diseases **2014**,		2
29	Determination of reference ultrasound parameters for model and hydrofluoroalkane propellants using high-resolution ultrasonic spectroscopy. *AAPS PharmSciTech*, **2008**, 9, 605-11	3.9	2
28	Effect of moisture on the compressibility and compactibility of sodium starch glycolate. *Pharmaceutical Development and Technology*, **2007**, 12, 217-22	3.4	2
27	The Development and Validation of an In Vitro Airway Model to Assess Realistic Airway Deposition and Drug Permeation Behavior of Orally Inhaled Products Across Synthetic Membranes. *Journal of Aerosol Medicine and Pulmonary Drug Delivery*, **2018**, 31, 103-108	3.8	2
26	Properties of rapamycin solid lipid nanoparticles for lymphatic access through the lungs & part I: the effect of size. *Nanomedicine*, **2020**, 15, 1927-1945	5.6	2
25	Nasal Powder Formulation of Tranexamic Acid and Hyaluronic Acid for the Treatment of Epistaxis. *Pharmaceutical Research*, **2020**, 37, 186	4.5	2
24	On the Use of Computational Fluid Dynamics (CFD) Modelling to Design Improved Dry Powder Inhalers. *Pharmaceutical Research*, **2021**, 38, 277-288	4.5	2
23	Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?. *Expert Opinion on Orphan Drugs*, **2018**, 6, 69-84	1.1	2
22	A Simple and Rapid Method for Deposition and Measurement of Drug Transport Across Air Interface Respiratory Epithelia. *AAPS PharmSciTech*, **2018**, 19, 3272-3276	3.9	2
21	Toxicity of curcumin nanoparticles towards alveolar macrophage: Effects of surface charges.. *Food and Chemical Toxicology*, **2022**, 163, 112976	4.7	2
20	The Development and Achievement of Polymeric Nanoparticles for Cancer Drug Treatment **2017**, 25-82		1
19	Using individualized three-dimensional printed airway models to guide airway stent implantation. *Interactive Cardiovascular and Thoracic Surgery*, **2020**, 31, 900-903	1.8	1
18	The effects of loaded carrier mass and formulation mass on aerosolization efficiency in dry powder inhaler devices. *Current Drug Delivery*, **2015**, 12, 40-6	3.2	1
17	Beating cilia identification in fluorescence microscope images for accurate CBF measurement **2015**,		1

16	Correlation between compactibility values and excipient cluster size using an in silico approach. *Drug Development and Industrial Pharmacy*, **2013**, 39, 374-81	3.6	1
15	Comparative measurements of pressurised metered dose inhaler (pMDI) stem displacement. *Drug Development and Industrial Pharmacy*, **2008**, 34, 90-4	3.6	1
14	Prospective nanoparticle treatments for lymphangioleiomyomatosis.. *Expert Opinion on Drug Delivery*, **2022**, 1-12	8	1
13	Combining experimental and computational techniques to understand and improve dry powder inhalers.. *Expert Opinion on Drug Delivery*, **2022**,	8	1
12	Selective shape-change response by anisotropic endoskeletal droplets. *Extreme Mechanics Letters*, **2020**, 35, 100618	3.9	1
11	Development and in vitro characterization of a novel pMDI diclofenac formulation as an inhalable anti-inflammatory therapy for cystic fibrosis. *International Journal of Pharmaceutics*, **2021**, 596, 120319	6.5	1
10	Increasing the fine particle fraction of pressurised metered dose inhaler solutions with novel actuator shapes. *International Journal of Pharmaceutics*, **2021**, 597, 120341	6.5	1
9	Delivery of pDNA Polyplexes to Bronchial and Alveolar Epithelial Cells Using a Mesh Nebulizer. *Pharmaceutical Research*, **2018**, 36, 14	4.5	1
8	How Do Mechanics Guide Fibroblast Activity? Complex Disruptions during Emphysema Shape Cellular Responses and Limit Research. *Bioengineering*, **2021**, 8,	5.3	1
7	Inhalation and Nasal Products **2013**, 15-30		0
6	An adaptable microreactor to investigate the influence of interfaces on Pseudomonas aeruginosa biofilm growth.. *Applied Microbiology and Biotechnology*, **2022**, 1	5.7	0
5	Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. *European Journal of Pharmacology*, **2021**, 902, 174098	5.3	0
4	Simulation of respiratory tract lining fluid for in vitro dissolution study. *Expert Opinion on Drug Delivery*, **2021**, 18, 1091-1100	8	0
3	Unique location but similar issues: working with health professionals in correctional services to improve inhaler use. *Journal of Pharmacy Practice and Research*, **2015**, 45, 276-281	0.7	
2	Motion Representation of Ciliated Cell Images with Contour-Alignment for Automated CBF Estimation. *Lecture Notes in Computer Science*, **2015**, 300-307	0.9	
1	Investigating Potential TRPV1 Positive Feedback to Explain TRPV1 Upregulation in Airway Disease States.. *Drug Development and Industrial Pharmacy*, **2022**, 1-42	3.6	